7 A-Rated Stocks to Buy for the Rest of 2015: Ambarella (AMBA)
Ambarella (AMBA) has been a tear almost since it went public in 2012. The stock is up almost 1,900% since its IPO, 300% in the past year and 145% year to date.
It is like bottled lightning — and the crazy thing is that its rise has only just begun.
AMBA has caught the tsunami of the online video-cation of literally everything. Now that bandwidth is becoming bigger and more accessible, particularly on mobile devices, videos of everything are popping up everywhere.
AMBA makes semiconductor processors for HD quality video. And its main client is GoPro (GPRO), maker of the small, rugged cameras that have taken the world by storm.
But GoPro is just the beginning. AMBA is a major player in technologies such as self-driving cars and unmanned aerial vehicles, which promise to be huge growth sectors as well.
AMBA is perfectly situated to take advantage of the enormous growth in both the consumer and industrial markets for its pioneering technology. This one has miles to run before it tires.
Sentiment: Strong Buy
Back up to $117.95. Its amazing how this clown with BS makes it to yahoo news but when there is reputable information and the stock goes up yahoo does not say release an article. Controlled media bs!
Thanks Sharon...this fish oil needs a big infusion of vitamin c injected in it! This has been a train wreck of epic proportions.
Shares of Synta Pharma. (NASDAQ: SNTA) are lower on Tuesday, a moved tied to the resignation of the company's R&D President Sumant Ramachandra. The resignation was revealed in SEC filings late on Monday, and no reason was given, leaving investors guessing.
Commenting, Roth Capital analyst Joseph Pantginis said the timing may be viewed as negative by investors ahead of Galaxy-1 data presentation at the ASCO meeting in June. However, he doesn't think the resignation is cause for concern. In fact, he sees today's sell-off as a buying opportunity, as he expects positive data at ASCO and plenty of positive news flow in the days ahead.
Roth Capital has a Buy rating on Synta Pharma. with a price target of $18.00